Skip to main navigation Skip to search Skip to main content

Evaluation of Treatment Outcomes of Prostate Cancer Patients with Lymph Node Metastasis Treated with Definitive Radiotherapy: Comparative Analysis of PSMA PET/CT and Conventional Imaging

  • Cem Onal
  • , Ozan Cem Guler
  • , Petek Erpolat
  • , Pervin Hurmuz
  • , Philip Sutera
  • , Matthew P. Deek
  • , Aysenur Elmali
  • , Melek Tugce Yilmaz
  • , Ummu Habibe Koken
  • , Melek Yavuz
  • , Gokhan Ozyigit
  • , Phuoc T. Tran

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose We investigated the impact of prostate-specific membrane antigen (PSMA) PET/CT compared with conventional imaging on treatment outcomes for node-positive prostate cancer (PCa) patients who underwent androgen deprivation therapy (ADT) and external radiotherapy (RT). Patients and Methods A multicentric, retrospective study recruited patients with node-positive PCa patients who underwent conventional radiological evaluation or PSMA PET/CT and received ADT and RT at 3 hospitals from 2009 to 2021 were enrolled. Patients underwent prostate and pelvis RT, accompanied by a minimum of 6 months of ADT. The primary endpoints were progression-free survival (PFS) and PCa-specific survival (PCSS). Cox regression analyzed the association of survival with potential prognostic factors, whereas logistic regression identified the predictors of bone and lymph node metastasis. Results The median follow-up time was 64.0 months. The majority of patients (64.1%) underwent PSMA PET/CT for staging. The 5-year rates of PFS and PCSS were 63.7% and 83.7%, respectively. Disease progression was observed in 90 patients (36.3%). In multivariable analysis, ADT duration of less than 24 months and post-RT prostate-specific antigen (PSA) nadir were prognostic for PFS. Early clinical T stage and PSMA PET/CT predicted better PCSS. Patients staged with PSMA PET/CT had exhibited significantly higher 5-year PCSS rates than compared with those staged with conventional imaging (95.1% vs 76.9%; P = 0.01). Shorter ADT duration and higher PSA levels after RT independently predicted bone metastasis in multivariable logistic regression. Advanced T stage, shorter ADT duration, and higher PSA levels after neoadjuvant ADT predicted nonregional lymph node recurrence. Conclusions ADT with pelvis RT is an effective treatment option for node-positive PCa patients. The PSMA PET/CT outperformed conventional imaging in PCSS, emphasizing the importance of precise clinical staging for patients undergoing definitive RT.

Original languageEnglish (US)
Pages (from-to)e383-e389
JournalClinical nuclear medicine
Volume49
Issue number8
DOIs
StatePublished - Aug 1 2024
Externally publishedYes

Keywords

  • androgen deprivation therapy
  • lymph node metastasis
  • prostate cancer
  • radiotherapy
  • survival

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Evaluation of Treatment Outcomes of Prostate Cancer Patients with Lymph Node Metastasis Treated with Definitive Radiotherapy: Comparative Analysis of PSMA PET/CT and Conventional Imaging'. Together they form a unique fingerprint.

Cite this